Please login to your online account to display your discounted pricing

Progesterone Receptor Mouse anti-Human, Biotin, Clone: KMC912, eBioscience™

Mouse Monoclonal Antibody

$143.55 - $346.55

Specifications

Antigen Progesterone Receptor
Clone KMC912
Host Species Mouse
Gene Alias PR, PgR
Species Reactivity Human
View More Specs

 Disclaimers

For Research Use Only.

Products
Catalog Number Mfr. No. Quantity Price Quantity    

501122604

 
affymetrix
13976480
25μg Each for $143.55

501122605

 
affymetrix
13976482
100μg Each for $346.55
Description & Specifications

Specifications

Antigen Progesterone Receptor
Clone KMC912
Host Species Mouse
Gene Alias PR, PgR
Species Reactivity Human
Applications Immunocytochemistry
Applications Immunohistochemistry (Formalin/Paraffin)
Applications Microscopy
Regulatory Status RUO
Conjugate Biotin
Format Conjugated
Storage Requirements Store at 2-8°C. Do not freeze.
Primary or Secondary Primary
Monoclonal or Polyclonal Monoclonal
Formulation aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Concentration 0.5mg/mL

This KMC912 monoclonal antibody reacts with human progesterone receptor (PgR, PR), a member of a superfamily of nuclear receptors that are ligand-dependent transcriptional regulators. The human PgR exists in alpha and beta forms, 94kDa and 120kDa respectively. In most human cells, the alpha and beta forms are expressed at similar levels and predominately form heterodimers. Progestin binding to PgR causes a conformational change, allowing dissociation of bound chaperone proteins and subsequent dimerization with either PgRa or PgRb. Following activation, dimerized PgR can directly bind to DNA through progestin response elements (PRE) leading to chromatin remodeling and subsequent downregulation or transcription of the target gene.The PgR plays a key role in controlling gene expression in breast, uterine, brain, and cardiovascular tissue during development. The presence of the PgR in breast tissue is indicative of improved survival and a better response to endocrine therapy. In breast and endometrial cancer progression, a predominance of either the alpha or beta form occurs, suggesting disregulation in the PgRa:PgRb ratio is an early event in cancer. In cases of ductal carcinoma in situ and invasive ductal carcinoma, there is predominance of the alpha form while in uterine cancer a loss of either form is common.